Hasenkamp, Justin

[["dc.bibliographiccitation.firstpage","341"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","348"],["dc.bibliographiccitation.volume","89"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Borgerding, Andrea"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Truemper, Lorenz H."],["dc.contributor.author","Glass, Bertram"],["dc.date.accessioned","2018-11-07T08:44:18Z"],["dc.date.available","2018-11-07T08:44:18Z"],["dc.date.issued","2010"],["dc.description.abstract","Natural killer (NK) cells contribute to the graft-versus-leukemia effect after allogeneic stem cell transplantation. However, the efficacy of NK cell-mediated tumor cell lysis is limited due to target cell resistance, and target cell-induced apoptosis (TiA) was proposed to contribute to differences in susceptibility to NK cells. Here we analyzed the effects of target cells on the apoptosis of cytokine-activated NK cells in vitro. We found no association of target cell susceptibility and TiA of NK cells in an array of human and murine target-effector cell combinations. Incubation of NK cells with caspase inhibitors blocked TiA incompletely, indicating that TiA is partly based on caspase-independent mechanisms. Modulating NK cell susceptibility against TiA by caspase inhibition did not influence cytotoxic efficacy. Furthermore, we found cytotoxic potential of NK cells to be markedly decreased following first target cell contact. Exhaustion of NK cell activity by first target cell contact was, however, not mediated by TiA. In addition, we found no relevant TiA by lymphoma cell lines against activated murine NK cells. We conclude that TiA represents only a minor factor of target cell resistance against NK cell-mediated cytolysis."],["dc.description.sponsorship","Deutsche Krebshilfe"],["dc.identifier.doi","10.1007/s00277-009-0844-1"],["dc.identifier.isi","000274685400002"],["dc.identifier.pmid","19823823"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?goescholar/4146"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20165"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","0939-5555"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Relevance of target cell-induced apoptosis as mechanism of resistance against natural killer cells"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","14"],["dc.contributor.affiliation","Shumilov, Evgenii; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Aperdannier, Lena; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Schmidt, Nicole; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Szuszies, Christoph; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Neesse, Albrecht; 3Department of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; albrecht.neesse@med.uni-goettingen.de"],["dc.contributor.affiliation","Hoffknecht, Petra; 4Department of Thorax Oncology, Franziskus-Hospital Harderberg, Niels-Stensen-Kliniken, 49124 Georgsmarienhütte, Germany; petra.hoffknecht@niels-stensen-kliniken.de"],["dc.contributor.affiliation","Khandanpour, Cyrus; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Mikesch, Jan-Henrik; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Stelljes, Matthias; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Boeckel, Göran Ramin; 6Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany; goeranramin.boeckel@ukmuenster.de (G.R.B.); phil-robin.tepasse@ukmuenster.de (P.-R.T.)"],["dc.contributor.affiliation","Tepasse, Phil-Robin; 6Department of Medicine B for Gastroenterology, Hepatology, Endocrinology and Clinical Infectiology, University Hospital Münster, 48149 Münster, Germany; goeranramin.boeckel@ukmuenster.de (G.R.B.); phil-robin.tepasse@ukmuenster.de (P.-R.T.)"],["dc.contributor.affiliation","Reitnauer, Lea; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Koch, Raphael; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Hasenkamp, Justin; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Bacher, Ulrike; 8Central Hematology Laboratory, Department of Hematology, Inselspital, Bern University Hospital, University of Bern, 3010 Bern, Switzerland; veraulrike.bacher@insel.ch"],["dc.contributor.affiliation","Scheithauer, Simone; 9Department of Infection Control and Infectious Diseases, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; simone.scheithauer@med.uni-goettingen.de"],["dc.contributor.affiliation","Trümper, Lorenz; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Schmitz, Norbert; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Wulf, Gerald; 2Department of Hematology and Medical Oncology, University Medicine Göttingen (UMG), 37077 Göttingen, Germany; lena.aperdannier@med.uni-goettingen.de (L.A.); nicole.schmidt@med.uni-goettingen.de (N.S.); christoph.szuszies@med.uni-goettingen.de (C.S.); raphael.koch@med.uni-goettingen.de (R.K.); justin.hasenkamp@med.uni-goettingen.de (J.H.); lorenz.truemper@med.uni-goettingen.de (L.T.); gerald.wulf@med.uni-goettingen.de (G.W.)"],["dc.contributor.affiliation","Kerkhoff, Andrea; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Lenz, Georg; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Krekeler, Carolin; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.affiliation","Bleckmann, Annalen; 1Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, 48149 Münster, Germany; cyrus.khandanpour@ukmuenster.de (C.K.); jan-henrik.mikesch@ukmuenster.de (J.-H.M.); matthias.stelljes@ukmuenster.de (M.S.); leaelisabeth.reitnauer@ukmuenster.de (L.R.); norbert.schmitz@ukmuenster.de (N.S.); andrea.kerkhoff@ukmuenster.de (A.K.); georg.lenz@ukmuenster.de (G.L.); carolin.krekeler@ukmuenster.de (C.K.)"],["dc.contributor.author","Shumilov, Evgenii"],["dc.contributor.author","Aperdannier, Lena"],["dc.contributor.author","Schmidt, Nicole"],["dc.contributor.author","Szuszies, Christoph"],["dc.contributor.author","Neesse, Albrecht"],["dc.contributor.author","Hoffknecht, Petra"],["dc.contributor.author","Khandanpour, Cyrus"],["dc.contributor.author","Mikesch, Jan-Henrik"],["dc.contributor.author","Stelljes, Matthias"],["dc.contributor.author","Boeckel, Göran Ramin"],["dc.contributor.author","Tepasse, Phil-Robin"],["dc.contributor.author","Reitnauer, Lea"],["dc.contributor.author","Koch, Raphael"],["dc.contributor.author","Hasenkamp, Justin"],["dc.contributor.author","Bacher, Ulrike"],["dc.contributor.author","Scheithauer, Simone"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Schmitz, Norbert"],["dc.contributor.author","Wulf, Gerald"],["dc.contributor.author","Kerkhoff, Andrea"],["dc.contributor.author","Lenz, Georg"],["dc.contributor.author","Krekeler, Carolin"],["dc.contributor.author","Bleckmann, Annalen"],["dc.date.accessioned","2022-08-03T14:40:37Z"],["dc.date.available","2022-08-03T14:40:37Z"],["dc.date.issued","2022-07-31"],["dc.date.updated","2022-08-03T12:15:44Z"],["dc.description.abstract","This study investigated SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated (n = 49) and non-vaccinated (n = 84) cancer patients. A mild course of COVID-19 was documented more frequently in vaccinated cancer patients (49% vs. 29%), while the incidence of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%). In comparison to non-vaccinated patients, admissions to intermediate and intensive care units and the need for non-invasive and invasive respiratory support were reduced by 71% and 50% among vaccinated patients. The median length of hospital stay was 11 days for non-vaccinated and 5 days for vaccinated patients. COVID-19 mortality was reduced by 83% in vaccinated patients. Finally, the median time from SARS-CoV-2 infection to restarting cancer therapy was 12 and 26 days among vaccinated and non-vaccinated groups, respectively. Our results provide evidence for the significant benefits of COVID-19 vaccines for cancer patients.\r\n \r\n \r\n Abstract\r\n COVID-19 vaccines have become an integral element in the protection of cancer patients against SARS-CoV-2. To date, there are no direct comparisons of the course of COVID-19 infection in cancer patients between the pre- and post-vaccine era. We analyzed SARS-CoV-2 infections and their impact on cancer in COVID-19 vaccinated and non-vaccinated patients from three German cancer centers. Overall, 133 patients with SARS-CoV-2 were enrolled in pre- and post-vaccine eras: 84 non-vaccinated and 49 vaccinated, respectively. A mild course of COVID-19 was documented more frequently in vaccinated patients (49% vs. 29%), while the frequency of severe and critical courses occurred in approximately one-half of the non-vaccinated patients (22% vs. 42%, p = 0.023). Particularly, patients with hematologic neoplasms benefited from vaccination in this context (p = 0.031). Admissions to intermediate- and intensive-care units and the necessity of non-invasive and invasive respiratory support were reduced by 71% and 50% among vaccinated patients, respectively. The median length of admission was 11 days for non-vaccinated and 5 days for vaccinated patients (p = 0.002). COVID-19 mortality was reduced by 83% in vaccinated patients (p = 0.046). Finally, the median time from SARS-CoV-2 infection to restarting cancer therapy was 12 and 26 days among vaccinated and non-vaccinated groups, respectively (p = 0.002). Although this study does not have enough power to perform multivariate analyses to account for confounders, it provides data on COVID-19 in non-vaccinated and vaccinated cancer patients and illustrates the potential benefits of COVID-19 vaccines for these patients."],["dc.identifier.doi","10.3390/cancers14153746"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/112610"],["dc.language.iso","en"],["dc.relation.eissn","2072-6694"],["dc.rights","CC BY 4.0"],["dc.title","Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.subtype","original_ja"],["dspace.entity.type","Publication"]]